Press Releases
Requires Acrobat Reader to view. Download here.
1.14.15 - Bellerophon Therapeutics Completes Enrollment in PRESERVATION I, a Trial of Bioabsorbable Cardiac Matrix (BCM) for the Prevention of Congestive Heart Failure After a Heart Attack
7.1.14 - Bellerophon Therapeutics Names Jonathan Peacock Chairman and Chief Executive Officer
6.26.14 - Bellerophon Therapeutics Completes Enrollment of its Phase 2 Trial of INOpulse® For Treatment of Pulmonary Hypertension Associated with Chronic Obstructive Pulmonary Disease (PH-COPD)
6.17.14 - Bellerophon Therapeutics Completes Enrollment for its Phase 2 Trial of INOpulse® For Treatment of Pulmonary Arterial Hypertension (PAH)
12.24.13 - IKARIA Shareholders Led By New Mountain Capital Reach Agreement To Split IKARIA Into Two Companies